Augusta University named NIH Specialized Center of Research Excellence on Sex Differences

Jun 22, 2025

5 min

Jennifer Sullivan, PhD

Jennifer C. Sullivan, PhD, dean of The Graduate School at Augusta University, has dedicated her research to better understand why blood pressure increases in hypertension and raising awareness to the dangers of not paying attention to heart health, particularly among women.


Throughout her career, Sullivan has been continuously funded by the National Institutes of Health (NIH) and the American Heart Association since becoming a tenure-track faculty member in 2008, and now she has a chance to take her research further after securing a five-year, $7.5 million grant to have Augusta University designated as a Specialized Center of Research Excellence on Sex Differences (SCORE) by the NIH’s Office of Research on Women’s Health.


It’s a distinction that places AU among 10 other leaders in research for the field, including Brigham and Women’s Hospital, Cedars-Sinai Medical Center, Emory University, Johns Hopkins University, Massachusetts General Hospital and Harvard Medical School, the Mayo Clinic, the Medical University of South Carolina, the University of Colorado and Yale University. The University of California, Los Angeles has two SCORE programs.



“I’m so proud and excited for this opportunity because this has been what I have focused my research program on for my entire career, and to be able to advance it with a program like this, where we can actually build a unique program focused on an area that can make a difference, is just so much fun,” Sullivan said. “Just the fact that Augusta will be included on this list, attached to an organization of the caliber of NIH, will provide opportunities that we’ve never had before, especially for our students and younger researchers.”


Sullivan’s SCORE project, “Improving awareness of women with hypertension: ROAR (Rural, Obese, At Risk),” focuses primarily on the fact that, while young women are considered “protected” from hypertension and the associated cardiovascular risk relative to age-matched men, the elimination of hypertension is projected to have a larger impact on cardiovascular disease (CVD) mortality in women.


“The group of people with the highest risk of death from hypertension is in the rural South of the U.S., specifically Black women are particularly vulnerable to developing hypertension and CVD,” Sullivan said.


According to Sullivan’s research and information available from the American Heart Association (AHA), approximately 19 million deaths were attributed to CVD globally in 2020, an increase of about 20% from 2010. Both Sullivan and the AHA state that cardiovascular disease remains the leading cause of death for both men and women in the United States, and that hypertension is a major modifiable risk factor for CVD.


Sullivan said, “It has been suggested that eliminating hypertension would reduce CVD mortality by over 30% in men and 38% in women, but a critical barrier to limiting premature death from CVD is lack of awareness surrounding the risks of CVD. Our overall goal in this new funded project is to transform academic and community understanding of sex as a biological variable in the consideration of hypertension.”


The three research projects include Sullivan’s lead project on high fat diets, a project on systemic lupus erythematosus (SLE) disproportionately affects young women led by Erin Taylor, PhD, at the University of Mississippi Medical Center, and another project looking at the role of inflammation and how immune cells are activated in SLE led by Michael Ryan, PhD, at the University of South Carlina’s School of Medicine.



But there is more to SCORE than just conducting research. Each SCORE team is also responsible for a career enhancement core and a leadership administrative core.


“What really sets these grants apart are the emphasis on the career enhancement and leadership administrative cores. The Career Enhancement Core is designed to be a bit open ended for each SCORE, but in talking to the NIH, what they were most excited about in our project is the community outreach piece we designed.

“Our grant includes people across the entire campus, including Augusta University’s Medical College of Georgia, the College of Allied Health Sciences, the College of Education and Human Development and multiple campus partners including some of our sororities on campus and the Center for Writing Excellence,” Sullivan said. “More specifically, the COEHD is able to extend our outreach efforts to our local schools to begin educating children on the importance of screening, and our sororities are obviously connected with other chapters across the southeast which helps us spread our message, as well.”


Sullivan notes that, through this portion of the project alone, there will be numerous opportunities to include students from Augusta University’s CAHS, College of Nursing, Department of Kinesiology, the Biomedical Sciences PhD program and the proposed School of Public Health.



Marlo Vernon, PhD, associate professor at MCG and researcher for the Georgia Cancer Center, and Amanda Behr, chair of the Medical Illustration Program in CAHS, are also involved in various stages of the project.


“The other thing the Career Enhancement Core will do is provide pilot grants to three research projects each year for early-stage investigators. We’ll also be able to fund sabbaticals for graduate students or postdocs to go someplace else and learn cutting edge techniques from other experts, so there is a lot built in that will help us support up-and-coming researchers,” Sullivan said.

“We’re now part of this consortium, and they have a once-a-year, in-person meeting at the NIH offices, so we’ll go to that for the first time this year, and what’s neat about it is they’re really promoting young investigators. Each grant can bring up to eight people, the our hope is that we will have the investigators funded by the pilot projects attend next year, giving those folks the opportunity to present and talk to program officers with the NIH and develop a pipeline of investigators committed to studying women’s health and sex as a biological variable.”


Sullivan is also looking to designate some of her summer graduate and undergraduate research positions to the project beginning next summer.


“The Graduate School already has a summer program to support undergraduates that we will be able to piggyback off of. We have set aside five slots in that program for this that will go to students studying the sex as a biological variable, and the applications for that program, STAR, is already open,” Sullivan said.

“We’re also planning a symposium in collaboration with the Physiology Department in April 2024. This is an annual event sponsored by the department, and this year they selected sex differences as the topic, so we are hoping to help increase exposure and attendance.”



Looking to know more about the amazing research happening at  Augusta?


To connect with Jennifer Sullivan, simply click on her icon ow to arrange an interview today.



Connect with:
Jennifer Sullivan, PhD

Jennifer Sullivan, PhD

Interim Provost and Dean of The Graduate School

Jennifer Sullivan, PhD, is an internationally recognized expert of sex differences in cardiovascular physiology and pathophysiology.

HypertensionCardiovascular PhysiologyPathophysiology Higher Education Administration

You might also like...

Check out some other posts from Augusta University

2 min

Fueling the Future of Cancer Immunotherapy: Gang Zhou’s Research Takes a Major Step Forward

Cancer immunotherapy has transformed how clinicians approach the treatment of certain blood cancers, but major limitations remain — especially when it comes to sustaining strong, long-lasting immune responses. Gang Zhou, PhD, a leading cancer immunologist at Augusta University’s Georgia Cancer Center and the Immunology Center of Georgia, is tackling these challenges head-on. Zhou’s work focuses on how T cells behave inside the body and how their performance can be enhanced to improve patient outcomes. His lab studies the forces that strengthen or weaken T cell responses, including their functional status, their ability to self-renew and the environmental pressures they face inside tumors. This deep understanding positions him as a key figure in the effort to advance next-generation immunotherapies. Recently, Zhou and his research team were awarded the first Ignite Grant from the Immunology Center of Georgia — a seed program designed to support bold, high-impact translational ideas. Their funded project aims to make CAR-T therapy more effective. CAR-T is a type of immunotherapy in which a patient’s own T cells are genetically modified to recognize and attack cancer cells. While this approach has revolutionized the treatment of certain blood cancers, it still faces obstacles such as limited cell persistence and reduced strength over time. “Our ultimate goal is to engineer T cells that not only survive longer but also remain highly functional, giving patients more durable protection against their disease.” Zhou’s team is addressing this issue by studying how a modified form of STAT5, a transcription factor that plays a key role in T cell survival and function, may help engineered T cells last longer and perform better. The ultimate goal is to create CAR-T therapies that maintain potency, withstand the harsh tumor microenvironment, and offer durable results for patients. The Ignite Grant recognizes not only the promise of this specific project, but also Zhou’s broader expertise in understanding how T cells can be guided, supported, and strengthened to fight cancer more effectively. His research contributes to a growing wave of scientific innovation aimed at improving immunotherapy outcomes for patients with both blood cancers and, potentially, solid tumors — an area where current treatments face significant barriers. As immunotherapy continues to evolve, the work led by Gang Zhou stands as a compelling example of how foundational science, translational research, and clinical ambition can work together to push the field forward. To connect with Dr. Gang Zhou - simply contact AU's External Communications Team mediarelations@augusta.edu to arrange an interview today.

3 min

MCG scientists investigate arthritis drug’s impact on Alzheimer’s disease

According to the Alzheimer’s Association, more than 7 million Americans are living with Alzheimer’s disease, and one in nine of those people is 65 or older. Although that number is expected to grow, researchers at the Medical College of Georgia at Augusta University are making progress on studies that could turn into life-saving treatments. Qin Wang, MD, PhD, professor in the Department of Neuroscience and Regenerative Medicine at MCG and Georgia Research Alliance Eminent Scholar in neuropharmacology, recently published a study titled “The PKCι‑β‑arrestin2 axis disrupts SORLA retrograde trafficking, driving its degradation and amyloid pathology in Alzheimer’s disease,” in Molecular Degeneration, a leading journal in neurodegeneration. In the study, Wang and her team explored how certain proteins and enzymes interact in the brains of Alzheimer’s patients. Key players include the SORL1 gene, the PKCι enzyme and proteins SORLA, β‑arrestin2 and amyloid. SORL1 encodes SORLA, which helps regulate amyloid. Amyloid can form plaque in the brain, contributing to Alzheimer’s. People with the disease often have lower SORLA levels, which amplifies plaque production. “The goal is to increase SORLA levels in patients with AD. If we can boost it up, that would be great,” Wang said. “But if you want to know how to boost it up, you have to know how it is degraded, so that’s what our work is about – we’re trying to understand how its stability is regulated.” Wang’s research team found that PKCι can add a phosphate group to SORLA, which helps SORLA interact with β‑arrestin2. The PKCι‑β‑arrestin2 axis leads to SORLA degradation, reducing its levels and allowing amyloid plaques to grow unchecked, thereby worsening the disease condition. They discovered this by using biochemical methods and a mass spectrometer managed by Wenbo Zhi, PhD, at the Proteomics and Mass Spectrometry core lab at AU. “We conducted biochemical studies and found that SORLA can be phosphorylated. We identified the phosphorylation site and the interacting enzymes,” Wang explained. “Using the mass spectrometer with PKCι, we saw increased phosphorylation of SORLA at certain sites. Preventing that could stop SORLA degradation.” That’s where a rheumatoid arthritis drug called auranofin comes into play. “While it is an arthritis drug, it can also inhibit the PKCι enzyme,” Wang explained. The team conducted tests using Alzheimer’s mouse models and human iPS cells developed into neurons. For the mouse models, they treated the mice with auranofin for eight weeks, resulting in decreased amyloid levels, reduced neuroinflammation and improved cognitive function. Similar results were seen in human cells with increased SORLA levels and decreased amyloid levels. “A good thing about this is, because this is an FDA-approved drug, it’s ready to be tested in Alzheimer’s patients,” Wang said. “People often worry about drug safety because of long-term use in chronic diseases like Alzheimer’s, but, in this case, existing safety data for chronic use gives a good starting point for testing in Alzheimer’s patients. “I hope a drug company can pick that up for a trial with Alzheimer’s patients because we are trying to translate our bench work all the way to the bedside for treatment,” she continued. The study wraps up a five-year National Institute on Aging grant, a collaborative effort between Wang’s lab and the Kai Jiao, MD, PhD, lab in AU’s Center of Biotechnology and Genomic Medicine. Wang’s team is also working on other grant-funded Alzheimer’s-related projects and hopes to continue making advancements toward finding a cure for this debilitating disease. “All of our projects share the goal of finding a better treatment,” Wang said. “Related to this project in particular, we want to know how the SORLA protein works in different types of brain cells, given the brain’s complexity. Then we can determine how to specifically target that protein to develop more effective therapies.” Qin Wang, MD, PhD, researches the neuropharmacology and signaling mechanisms underlying neurological and psychiatric disorders. If you're interested in learning more about her work or booking an interview,  simply click on her icon now to arrange a time to talk.

2 min

Experts in the Media: CBD may help treat and reduce inflammation in Alzheimer's disease

In a recent Medical News Today article, Corrie Pelc reported on a study led by Babak Baban, PhD, in which inhaled CBD (cannabidiol) was tested in a mouse model of Alzheimer’s disease to examine its effects on neuroinflammation. Baban, associate dean for Research with AU's Dental College of Georgia and a professor with appointments in neurology and surgery in the Medical College of Georgia at Augusta University, explained that previous work from his group showed inhaled CBD to be more effective than oral or injected forms for certain neurological conditions, motivating them to explore its potential in Alzheimer’s research. He emphasized that Alzheimer’s is driven by multiple interacting biological processes – not just amyloid plaques – and sees inflammation as a promising new therapeutic target. In the study, inhaled CBD lowered activity in two major immune “alarm” pathways – IDO (indoleamine 2,3-dioxygenase) and cGAS-STING – both implicated in chronic inflammation. By dampening these pathways, CBD reduced levels of inflammatory cytokines and helped restore a more balanced immune environment in the brain. Baban framed this as a shift from symptom treatment to addressing underlying immune dysfunction, and noted that the findings could reorient how Alzheimer’s is approached. At the same time, he stressed that human trials are still needed: his team is preparing translational studies and holds an active Investigational New Drug (IND) application with the FDA for inhaled CBD in neuroinflammatory conditions, with Alzheimer’s disease as a natural next step. Read the full article here: Babak Baban, PhD, is a professor, immunologist and associate dean for research at the Dental College of Georgia at Augusta University where he has served for 13 of his 20 years as a translational and clinical immunologist. View his profile here Looking to know more about this important research or to connect with Babak Baban, PhD? He's available to speak with media – simply click on his icon to arrange an interview today.

View all posts